Samlyn Capital LLC Purchases 28,312 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Samlyn Capital LLC boosted its position in Janux Therapeutics, Inc. (NASDAQ:JANX) by 9.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 324,703 shares of the company’s stock after buying an additional 28,312 shares during the period. Samlyn Capital LLC owned approximately 0.63% of Janux Therapeutics worth $13,602,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Amalgamated Bank increased its position in Janux Therapeutics by 61.1% in the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after buying an additional 368 shares in the last quarter. Summit Securities Group LLC bought a new stake in Janux Therapeutics in the 2nd quarter valued at about $29,000. Plato Investment Management Ltd bought a new stake in Janux Therapeutics in the 2nd quarter valued at about $42,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Janux Therapeutics during the 2nd quarter valued at about $151,000. Finally, Quest Partners LLC boosted its stake in Janux Therapeutics by 307.2% during the 2nd quarter. Quest Partners LLC now owns 5,795 shares of the company’s stock valued at $243,000 after purchasing an additional 4,372 shares during the last quarter. 75.39% of the stock is owned by institutional investors.

Insider Activity at Janux Therapeutics

In related news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $42.00, for a total value of $4,551,330.00. Following the transaction, the insider now owns 3,162,851 shares in the company, valued at $132,839,742. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last quarter, insiders have sold 268,578 shares of company stock worth $12,071,151. Insiders own 35.40% of the company’s stock.

Janux Therapeutics Stock Up 0.1 %

Shares of NASDAQ JANX opened at $50.26 on Tuesday. Janux Therapeutics, Inc. has a twelve month low of $5.65 and a twelve month high of $65.60. The stock’s 50 day moving average price is $43.69 and its 200-day moving average price is $44.37. The company has a market capitalization of $2.61 billion, a PE ratio of -41.20 and a beta of 3.57.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.20. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. The firm had revenue of $8.90 million for the quarter, compared to the consensus estimate of $0.77 million. The business’s revenue was up 709.1% compared to the same quarter last year. As a group, research analysts expect that Janux Therapeutics, Inc. will post -1.18 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have issued reports on JANX. Cantor Fitzgerald reiterated an “overweight” rating and set a $100.00 price target on shares of Janux Therapeutics in a research note on Monday, September 16th. Scotiabank cut their price target on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a research note on Friday, August 9th. Stifel Nicolaus began coverage on Janux Therapeutics in a research note on Friday, September 6th. They set a “buy” rating and a $70.00 price target for the company. Wedbush reiterated an “outperform” rating and set a $74.00 price target on shares of Janux Therapeutics in a research note on Thursday, August 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $63.00 price target on shares of Janux Therapeutics in a research note on Monday, August 19th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $66.13.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.